Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.

Damaj G, Joris M, Chandesris O, Hanssens K, Soucie E, Canioni D, Kolb B, Durieu I, Gyan E, Livideanu C, Chèze S, Diouf M, Garidi R, Georgin-Lavialle S, Asnafi V, Lhermitte L, Lavigne C, Launay D, Arock M, Lortholary O, Dubreuil P, Hermine O.

PLoS One. 2014 Jan 21;9(1):e85362. doi: 10.1371/journal.pone.0085362. eCollection 2014.

2.

Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.

Jawhar M, Schwaab J, Schnittger S, Sotlar K, Horny HP, Metzgeroth G, Müller N, Schneider S, Naumann N, Walz C, Haferlach T, Valent P, Hofmann WK, Cross NC, Fabarius A, Reiter A.

Leukemia. 2015 May;29(5):1115-22. doi: 10.1038/leu.2015.4. Epub 2015 Jan 8.

PMID:
25567135
3.

Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.

Wang SA, Hutchinson L, Tang G, Chen SS, Miron PM, Huh YO, Jones DM, Bueso-Ramos C, Verstovsek S, Medeiros LJ, Miranda RN.

Am J Hematol. 2013 Mar;88(3):219-24. doi: 10.1002/ajh.23380.

4.

Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).

Sotlar K, Colak S, Bache A, Berezowska S, Krokowski M, Bültmann B, Valent P, Horny HP.

J Pathol. 2010 Apr;220(5):586-95. doi: 10.1002/path.2677.

PMID:
20112369
5.
6.

Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.

Traina F, Visconte V, Jankowska AM, Makishima H, O'Keefe CL, Elson P, Han Y, Hsieh FH, Sekeres MA, Mali RS, Kalaycio M, Lichtin AE, Advani AS, Duong HK, Copelan E, Kapur R, Olalla Saad ST, Maciejewski JP, Tiu RV.

PLoS One. 2012;7(8):e43090. doi: 10.1371/journal.pone.0043090. Epub 2012 Aug 15.

7.

Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.

Valent P.

Hematology Am Soc Hematol Educ Program. 2015;2015:98-105. doi: 10.1182/asheducation-2015.1.98. Review.

PMID:
26637707
8.

Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies.

Pardanani A, Lim KH, Lasho TL, Finke C, McClure RF, Li CY, Tefferi A.

Blood. 2009 Oct 29;114(18):3769-72. doi: 10.1182/blood-2009-05-220145. Epub 2009 Aug 27.

9.

Comprehensive mutational profiling in advanced systemic mastocytosis.

Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, Kohlmann A, Grossmann V, Meggendorfer M, Horny HP, Valent P, Jawhar M, Teichmann M, Metzgeroth G, Erben P, Ernst T, Hochhaus A, Haferlach T, Hofmann WK, Cross NC, Reiter A.

Blood. 2013 Oct 3;122(14):2460-6. doi: 10.1182/blood-2013-04-496448. Epub 2013 Aug 19.

10.

Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations.

Pullarkat VA, Bueso-Ramos C, Lai R, Kroft S, Wilson CS, Pullarkat ST, Bu X, Thein M, Lee M, Brynes RK.

Am J Hematol. 2003 May;73(1):12-7.

11.

Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.

Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K, Horny HP, Metzgeroth G, Kluger S, Naumann N, Haferlach C, Haferlach T, Valent P, Hofmann WK, Fabarius A, Cross NC, Reiter A.

Leukemia. 2016 Jan;30(1):136-43. doi: 10.1038/leu.2015.284. Epub 2015 Oct 14.

PMID:
26464169
12.

KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance.

Schwaab J, Umbach R, Metzgeroth G, Naumann N, Jawhar M, Sotlar K, Horny HP, Gaiser T, Hofmann WK, Schnittger S, Cross NC, Fabarius A, Reiter A.

Am J Hematol. 2015 Sep;90(9):774-7. doi: 10.1002/ajh.24075. Epub 2015 Aug 14.

13.

The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.

Erben P, Schwaab J, Metzgeroth G, Horny HP, Jawhar M, Sotlar K, Fabarius A, Teichmann M, Schneider S, Ernst T, Müller MC, Giehl M, Marx A, Hartmann K, Hochhaus A, Hofmann WK, Cross NC, Reiter A.

Ann Hematol. 2014 Jan;93(1):81-8. doi: 10.1007/s00277-013-1964-1. Epub 2013 Nov 27.

PMID:
24281161
14.

Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.

Sotlar K, Bache A, Stellmacher F, Bültmann B, Valent P, Horny HP.

J Mol Diagn. 2008 Jan;10(1):58-66. doi: 10.2353/jmoldx.2008.070061. Epub 2007 Dec 28. Erratum in: J Mol Diagn. 2009 May;10(3):276.

15.

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.

Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Finke CM, Mullally A, Li CY, Pardanani A, Gilliland DG.

Leukemia. 2009 May;23(5):900-4. doi: 10.1038/leu.2009.37. Epub 2009 Mar 5.

16.

Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.

Jawhar M, Schwaab J, Horny HP, Sotlar K, Naumann N, Fabarius A, Valent P, Cross NC, Hofmann WK, Metzgeroth G, Reiter A.

Eur J Clin Invest. 2016 May;46(5):392-7. doi: 10.1111/eci.12607. Epub 2016 Mar 21.

PMID:
26914980
17.

Systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease: a clinicopathologic review.

Stoecker MM, Wang E.

Arch Pathol Lab Med. 2012 Jul;136(7):832-8. doi: 10.5858/arpa.2011-0325-RS. Review.

PMID:
22742558
18.

Molecular defects in mastocytosis: KIT and beyond KIT.

Bibi S, Langenfeld F, Jeanningros S, Brenet F, Soucie E, Hermine O, Damaj G, Dubreuil P, Arock M.

Immunol Allergy Clin North Am. 2014 May;34(2):239-62. doi: 10.1016/j.iac.2014.01.009.

PMID:
24745672
19.

Clinical and Molecular Diagnostic Evaluation of Systemic Mastocytosis in the South-Eastern Hungarian Population Between 2001-2013--A Single Centre Experience.

Marton I, Krenács L, Bagdi E, Bakos A, Demeter J, Borbényi Z.

Pathol Oncol Res. 2016 Apr;22(2):293-9. doi: 10.1007/s12253-015-9948-1. Epub 2015 Nov 6.

PMID:
26545382
20.

How I treat patients with advanced systemic mastocytosis.

Valent P, Sperr WR, Akin C.

Blood. 2010 Dec 23;116(26):5812-7. doi: 10.1182/blood-2010-08-292144. Epub 2010 Sep 20.

Supplemental Content

Support Center